Navigation Links
Agendia Introduces the SYMPHONY™ Breast Cancer Profile With Paraffin Embedded Tissue

IRVINE, Calif. and AMSTERDAM, Dec. 6, 2011 /PRNewswire/ -- Agendia, an innovative molecular diagnostics company, today announced the introduction of formalin fixed, paraffin embedded tissue technology applied to their Symphony™ suite of breast cancer assays. Delivering Agendia's tests in a paraffin embedded tissue format offers their customers added convenience along with the superior science, development and validation found in Agendia's breast cancer Symphony suite.

"Agendia's Symphony suite provides physicians with clear insight, helping them to choose a treatment protocol customized for each patient's individual needs," said Agendia's CEO, David Macdonald. "The use of paraffin embedded tissue with these tests will further assist physicians in delivering personalized treatment options."

Agendia's breast cancer Symphony suite of products leverage the predictive and prognostic power of four separate and distinct assays to provide a comprehensive decision support system.  Symphony assists physicians in determining which patients will benefit from chemo therapy, hormonal therapy, or combination therapies, preventing unnecessary suffering from short and long term side effects and burdensome costs to the overall health care system. Symphony includes MammaPrint®, which determines the risk of recurrence;  BluePrint™ determines molecular subtypes; TargetPrint® determines ER, PR and HER2 status; and TheraPrint® identifies alternative types of therapy for metastatic disease.

MammaPrint was the first in vitro Diagnostic Multivariate Index Assay (IVDMIA) to acquire clearance from the US Food and Drug Administration (FDA).  Originally offered for fresh tissue specimens, MammaPrint accurately identifies the risk of disease recurrence for patients with early stage breast cancer.

About Agendia:

Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, BluePrint­­, a molecular subtyping assay, TargetPrint, an ER/PR/HER2 expression assay, and TheraPrint, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of breast cancer tests, Agendia has a rich pipeline of genomic products in development based on its world-class quantitative gene expression platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2, MINDACT as well as other trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Irvine, California, United States, and Amsterdam, the Netherlands. For more information, please visit

For further information, please contact:

Ricochet Public Relations
Todd Aydelotte
Tel: +1 212 679 3300 ext. 111

SOURCE Agendia
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Appoints New CEO and Supervisory Board Member
2. Agendia Receives €1.27 Million in Funding from the EUs Seventh Framework Programme
3. Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
4. Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
5. Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
6. FDA Broadens Clearance for Agendias MammaPrint(R)
7. /C O R R E C T I O N -- Agendia B.V./
8. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
9. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
10. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
11. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
Post Your Comments:
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 25, 2015 , ... On November 10, 2015, Bohrer Brady, LLC filed a ... behalf of a home health care worker who provided companionship services for the elderly, ... workers employed by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article published November ... more widely heralded as a breakthrough for performing hernia repairs. The article explains that ... surgery is that it can greatly reduce the pain that a patient might otherwise ...
(Date:11/25/2015)... OH (PRWEB) , ... November 25, 2015 , ... Dental ... implants in Cleveland, OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant ... this year in Cleveland, OH. , As the co-founders of Advanced Implant Mentoring ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... athletic programs, launches new Wimbledon Athletics Facebook page to educate the ... for unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy Products, ... personal heating products business. Cozy Products explains what this means for business moving forward. ... with the Cozy Products business model: to sell personal heaters that reduce energy consumption, ...
Breaking Medicine News(10 mins):